[Inhibition by propranolol of the ouabain binding to myocardium]

Area of Science:

• Pharmacology
• Biochemistry
• Cardiovascular Science

Background:

• Cardiac glycosides, like ouabain, are vital for regulating cardiac function and ion transport.
• Na+, K+-ATPase is a crucial enzyme in maintaining cellular ion gradients.
• Propranolol is a beta-adrenergic blocker with known cardiovascular effects.

Purpose of the Study:

• To investigate the effect of propranolol on ouabain binding to heart and kidney tissues.
• To determine the mechanism by which propranolol influences Na+, K+-ATPase activity.
• To ascertain if propranolol's effect on cardiac glycosides is mediated by beta-adrenergic blockade.

Main Methods:

• Enriched fractions of heart and kidney medulla were used to assess ouabain binding.
• Na+, K+-ATPase activity was measured in the presence of varying propranolol concentrations.
• Complex II formation was promoted to evaluate its influence on propranolol's inhibitory effect.
• Stereospecificity and concentration-dependent effects of propranolol were analyzed.

Main Results:

• Propranolol significantly reduced the amount of ouabain bound to heart and kidney fractions.
• The inhibitory effect of propranolol on ouabain binding was enhanced when complex II formation was promoted.
• Propranolol decreased Na+, K+-ATPase activity by reducing the number of active sites, without altering ionic affinity.
• The observed effects were concentration-dependent (greater than 10(-4)M) and lacked stereospecificity, indicating independence from beta-adrenergic blockade.

Conclusions:

• Propranolol directly interferes with the binding of cardiac glycosides to their receptors in heart and kidney tissues.
• The reduction in Na+, K+-ATPase activity by propranolol is a direct effect on the enzyme's active sites, not mediated by beta-adrenergic blockade.
• These findings suggest a potential mechanism for reduced cardiac glycoside effectiveness when co-administered with propranolol.